Relaxes vascular smooth muscle, releases nitric oxide (NO), activates guanylate cyclase, and increases cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, reducing myocardial oxygen consumption, increasing oxygen supply, and relieving angina pectoris.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

Quinolone antibiotics interfere with bacterial DNA synthesis by acting on bacterial DNA gyrase, thus causing bacterial death. They have antibacterial effects on Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Serratia, Salmonella typhi, Shigella, Pseudomonas aeruginosa, etc.

This product is a broad-spectrum antibiotic that inhibits the early synthesis of bacterial cell walls, causing bacterial cell wall synthesis to be inhibited and leading to their death. It has a certain antibacterial effect on most Gram-positive and Gram-negative bacteria, and the antibacterial spectrum includes Staphylococcus aureus, Escherichia coli, Shigella, Serratia, Shigella, Pseudomonas aeruginosa, Klebsiella pneumoniae and Enterobacter aerogenes.

This product is a drug that inhibits the synthesis of uric acid. Allopurinol and its metabolite oxypurinol can inhibit xanthine oxidase, preventing hypoxanthine and xanthine from being metabolized into uric acid, thereby reducing the production of uric acid. It reduces the uric acid content in the blood and urine to a level below the solubility, prevents uric acid from forming crystals and depositing in joints and other tissues, and also helps to redissolve uric acid crystals in the tissues of gout patients. Allopurinol also inhibits the synthesis of new purines in the body by acting on hypoxanthine-guanine phosphate nucleic acid transferase. The blood uric acid concentration begins to decrease 24 hours after oral administration of this product, and the decrease is most obvious in 2 to 4 weeks.